Man Kin Tam Biography and Net Worth

CFO of Adagene

Mr. Man Kin (Raymond) Tam has served as our Chief Financial Officer since September 2019 and our director since February 2021. Mr. Tam has over 20 years of management experience in finance and banking across Asia-Pacific. Prior to Adagene, Mr. Tam served as Chief Financial Officer of different corporations including AgenTus Therapeutics, Inc. and China Regenerative Medicine International Limited. Mr. Tam also served as Project Director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited. Further, he held various management positions with J.P. Morgan and HSBC from 1999 to 2010. Mr. Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder.

Mr. Tam obtained an Executive Master of Business Administration degree from the University of Western Ontario in Canada in 2005, a Master of Practising Accounting degree from the Monash University in Australia in 2001 and a Bachelor of Civil & Resources Engineering (with First Class Honors) degree from the University of Auckland in New Zealand in 1998.

What is Man Kin Tam's net worth?: The estimated net worth of Man Kin Tam is at least $35.16 thousand as of September 23rd, 2026. Mr. Tam owns 12,000 shares of Adagene stock worth more than $35,160 as of September 28th. This net worth approximation does not reflect any other investments that Mr. Tam may own. Learn More about Man Kin Tam's net worth.
How do I contact Man Kin Tam?: The corporate mailing address for Mr. Tam and other Adagene executives is Building C14, Suzhou, JS, 215123. Adagene can also be reached via phone at 86-512-8777-3632 and via email at [email protected]. Learn More on Man Kin Tam's contact information.
Has Man Kin Tam been buying or selling shares of Adagene?: Within the last three months, Man Kin Tam has bought $6,000.00 of Adagene stock. Most recently, on Wednesday, September 23rd, Man Kin Tam bought 2,000 shares of Adagene stock. The stock was acquired at an average cost of $3.00 per share, with a total value of $6,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,000 shares of the company's stock, valued at $36,000. Learn More on Man Kin Tam's trading history.
Who are Adagene's active insiders?: Adagene's insider roster includes Peter Luo (CEO), and Man Kin Tam (CFO). Learn More on Adagene's active insiders.
Are insiders buying or selling shares of Adagene?: In the last twelve months, Adagene insiders bought shares 5 times. They purchased a total of 47,535 shares worth more than $162,257.75. The most recent insider tranaction occured on September, 23rd when CFO Man Kin Tam bought 2,000 shares worth more than $6,000.00. Insiders at Adagene own 21.2% of the company. Learn More about insider trades at Adagene.
Information on this page was last updated on 9/23/2026.

Man Kin Tam Insider Trading History at Adagene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/23/2026	Buy	2,000	$3.00	$6,000.00	12,000

Man Kin Tam Buying and Selling Activity at Adagene

Adagene Company Overview

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Today's Range

Now: $2.93

$2.87

$3.19

50 Day Range

MA: $3.61

$2.93

$4.23

2 Week Range

Now: $2.93

$1.30

$4.85

Volume

196,887 shs

Average Volume

209,513 shs

Market Capitalization

$193.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56